Senior Director, Search & Evaluation Late Ta Lead, Immunology
CSL SEQIRUS
Waltham, MA, USA
Base: $308,000 - $377,000; bonus/equity: may inclu...
Hybrid (3 days onsite)
Strategic sourcing of late-stage assets
Engage with external kols
Drive cross-functional due diligence
CSL Seqirus is seeking a Senior Director, Search & Evaluation Late TA Lead in Immunology, with a focus on strategic sourcing and evaluation of later-stage assets. This hybrid role requires deep clinical expertise and extensive engagement with key opinion leaders in the therapeutic areas of immunology, hematology, and cardiovascular/renal
Job Summary
Senior Directors of Search & Evaluation will lead strategic sourcing and evaluation of later-stage external Hematology therapeutic area opportunities from Phase 2 through marketed drugs.
The role is critical to shaping our portfolio through high-impact partnerships and transactions, requiring deep clinical expertise and strong engagement with external Key Opinion Leaders.
CSL's R&D organization is accelerating innovation to deliver greater impact for patients, building a future-ready team that thrives in dynamic biotech ecosystems.
Matching Summary
Match Score: 85
CSL Seqirus is seeking a Senior Director, Search & Evaluation Late TA Lead in Immunology, with a focus on strategic sourcing and evaluation of later-stage assets. This hybrid role requires deep clinical expertise and extensive engagement with key opinion leaders in the therapeutic areas of immunology, hematology, and cardiovascular/renal.
Salary
Base: $308,000 - $377,000; Bonus/Equity: May include incentive compensation and equity; Benefits: Not specified
Skills & Requirements
Must-have
strategic sourcing of late-stage assets
engage with external KOLs
drive cross-functional due diligence
deep clinical expertise in Immunology
Nice-to-have
influence therapeutic strategy
anticipate competitive dynamics
agile team committed to developing therapies
Key Requirements
15+ years in biopharma
Advanced degree (MD, PhD, or equivalent)
Proven track record of sourcing and closing late-stage deals